Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes?

Roberto Latagliata, Maria Antonietta Aloe Spiriti, Giuseppe Avvisati, Cinzia De Gregoris, Paola Fazi, Antonio Spadea, Maria Concetta Petti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) evolve in overt acute nonlymphocytic leukemia (ANLL) in about 40% of patients: the treatment of ANLL-MDS is not yet well clarified. To identify the role for aggressive and conservative approaches in ANLL-MDS, we evaluated retrospectively 78 patients in a 7-year period. Thirty-one patients (16 males and 15 females, median age 57.5 years, median MDS duration 5.5 months) were eligible for aggressive chemotherapy; 17 patients (54.8%) achieved complete remission (CR), 10 (32.3%) were resistant and 4 (12.9%) died during induction from infective complications. All patients that achieved CR relapsed, with a median CR duration of 6 months (range 2-28 months); median survival of the whole group was 8.5 months, while median survival of responders was 9 months. No prognostic factor revealed a statistical significance in the outcome, due to the small number of patients in each subgroup. Forty-seven patients (27 male and 20 female, median age 71.8 years, median MDS duration 10.1 months) were not eligible for aggressive chemotherapy; 16 patients (34.2%) received supportive care only, 31 patients (65.8%) needed conservative chemotherapy for disease progression. Median survival of the conservatively treated group was 5.5 months, without statistical difference from the aggressively treated group; 10 47 conservatively treated patients (21%) survived for longer than 12 months. In conclusion, aggressive chemotherapy may play a role only in a selected population of ANLL-MDS patients, while further studies could be helpful to identify the optimal conservative approach.

Original languageEnglish
Pages (from-to)213-217
Number of pages5
JournalLeukemia Research
Volume19
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Drug Therapy
Survival
Disease Progression

Keywords

  • Acute leukemias
  • aggressive chemotherapy
  • conservative care
  • myelodysplastic syndromes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes? / Latagliata, Roberto; Spiriti, Maria Antonietta Aloe; Avvisati, Giuseppe; De Gregoris, Cinzia; Fazi, Paola; Spadea, Antonio; Petti, Maria Concetta.

In: Leukemia Research, Vol. 19, No. 3, 1995, p. 213-217.

Research output: Contribution to journalArticle

Latagliata, Roberto ; Spiriti, Maria Antonietta Aloe ; Avvisati, Giuseppe ; De Gregoris, Cinzia ; Fazi, Paola ; Spadea, Antonio ; Petti, Maria Concetta. / Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes?. In: Leukemia Research. 1995 ; Vol. 19, No. 3. pp. 213-217.
@article{0b733ee0f6174caf996362b0e12ab904,
title = "Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes?",
abstract = "Myelodysplastic syndromes (MDS) evolve in overt acute nonlymphocytic leukemia (ANLL) in about 40{\%} of patients: the treatment of ANLL-MDS is not yet well clarified. To identify the role for aggressive and conservative approaches in ANLL-MDS, we evaluated retrospectively 78 patients in a 7-year period. Thirty-one patients (16 males and 15 females, median age 57.5 years, median MDS duration 5.5 months) were eligible for aggressive chemotherapy; 17 patients (54.8{\%}) achieved complete remission (CR), 10 (32.3{\%}) were resistant and 4 (12.9{\%}) died during induction from infective complications. All patients that achieved CR relapsed, with a median CR duration of 6 months (range 2-28 months); median survival of the whole group was 8.5 months, while median survival of responders was 9 months. No prognostic factor revealed a statistical significance in the outcome, due to the small number of patients in each subgroup. Forty-seven patients (27 male and 20 female, median age 71.8 years, median MDS duration 10.1 months) were not eligible for aggressive chemotherapy; 16 patients (34.2{\%}) received supportive care only, 31 patients (65.8{\%}) needed conservative chemotherapy for disease progression. Median survival of the conservatively treated group was 5.5 months, without statistical difference from the aggressively treated group; 10 47 conservatively treated patients (21{\%}) survived for longer than 12 months. In conclusion, aggressive chemotherapy may play a role only in a selected population of ANLL-MDS patients, while further studies could be helpful to identify the optimal conservative approach.",
keywords = "Acute leukemias, aggressive chemotherapy, conservative care, myelodysplastic syndromes",
author = "Roberto Latagliata and Spiriti, {Maria Antonietta Aloe} and Giuseppe Avvisati and {De Gregoris}, Cinzia and Paola Fazi and Antonio Spadea and Petti, {Maria Concetta}",
year = "1995",
doi = "10.1016/0145-2126(94)00140-6",
language = "English",
volume = "19",
pages = "213--217",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "3",

}

TY - JOUR

T1 - Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes?

AU - Latagliata, Roberto

AU - Spiriti, Maria Antonietta Aloe

AU - Avvisati, Giuseppe

AU - De Gregoris, Cinzia

AU - Fazi, Paola

AU - Spadea, Antonio

AU - Petti, Maria Concetta

PY - 1995

Y1 - 1995

N2 - Myelodysplastic syndromes (MDS) evolve in overt acute nonlymphocytic leukemia (ANLL) in about 40% of patients: the treatment of ANLL-MDS is not yet well clarified. To identify the role for aggressive and conservative approaches in ANLL-MDS, we evaluated retrospectively 78 patients in a 7-year period. Thirty-one patients (16 males and 15 females, median age 57.5 years, median MDS duration 5.5 months) were eligible for aggressive chemotherapy; 17 patients (54.8%) achieved complete remission (CR), 10 (32.3%) were resistant and 4 (12.9%) died during induction from infective complications. All patients that achieved CR relapsed, with a median CR duration of 6 months (range 2-28 months); median survival of the whole group was 8.5 months, while median survival of responders was 9 months. No prognostic factor revealed a statistical significance in the outcome, due to the small number of patients in each subgroup. Forty-seven patients (27 male and 20 female, median age 71.8 years, median MDS duration 10.1 months) were not eligible for aggressive chemotherapy; 16 patients (34.2%) received supportive care only, 31 patients (65.8%) needed conservative chemotherapy for disease progression. Median survival of the conservatively treated group was 5.5 months, without statistical difference from the aggressively treated group; 10 47 conservatively treated patients (21%) survived for longer than 12 months. In conclusion, aggressive chemotherapy may play a role only in a selected population of ANLL-MDS patients, while further studies could be helpful to identify the optimal conservative approach.

AB - Myelodysplastic syndromes (MDS) evolve in overt acute nonlymphocytic leukemia (ANLL) in about 40% of patients: the treatment of ANLL-MDS is not yet well clarified. To identify the role for aggressive and conservative approaches in ANLL-MDS, we evaluated retrospectively 78 patients in a 7-year period. Thirty-one patients (16 males and 15 females, median age 57.5 years, median MDS duration 5.5 months) were eligible for aggressive chemotherapy; 17 patients (54.8%) achieved complete remission (CR), 10 (32.3%) were resistant and 4 (12.9%) died during induction from infective complications. All patients that achieved CR relapsed, with a median CR duration of 6 months (range 2-28 months); median survival of the whole group was 8.5 months, while median survival of responders was 9 months. No prognostic factor revealed a statistical significance in the outcome, due to the small number of patients in each subgroup. Forty-seven patients (27 male and 20 female, median age 71.8 years, median MDS duration 10.1 months) were not eligible for aggressive chemotherapy; 16 patients (34.2%) received supportive care only, 31 patients (65.8%) needed conservative chemotherapy for disease progression. Median survival of the conservatively treated group was 5.5 months, without statistical difference from the aggressively treated group; 10 47 conservatively treated patients (21%) survived for longer than 12 months. In conclusion, aggressive chemotherapy may play a role only in a selected population of ANLL-MDS patients, while further studies could be helpful to identify the optimal conservative approach.

KW - Acute leukemias

KW - aggressive chemotherapy

KW - conservative care

KW - myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=0028947107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028947107&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(94)00140-6

DO - 10.1016/0145-2126(94)00140-6

M3 - Article

VL - 19

SP - 213

EP - 217

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 3

ER -